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SUMMARY
We compared the relative risks of mother-to-child transmission of Toxoplasma gondii and
clinical manifestations due to congenital toxoplasmosis associated with intensive prenatal
treatment in Lyon and Austria, short term treatment in 51% of Dutch women, and no
treatment in Danish women. For each cohort, relative risks were standardized for gestation at
seroconversion. In total, 856 mother±child pairs were studied: 549 in Lyon, 133 in Austria, 123
in Denmark and 51 in The Netherlands. The relative risk for mother-to-child transmission
compared to Lyon was 1±24 (95% CI: 0±88, 1±59) in Austria; 0±59 (0±41, 0±81) in Denmark; and
0±65 (0±37, 1±01) in The Netherlands. Relative risks for clinical manifestations compared with
Lyon (adjusted for follow-up to age 3 years) were: Austria 0±19 (0±04, 0±51); Denmark 0±60
(0±13, 1±08); and The Netherlands 1±46 (0±51, 2±72). There was no clear evidence that the risk of
transmission or of clinical manifestations was lowest in centres with the most intensive prenatal
treatment.
INTRODUCTION
Routine testing of pregnant women to detect and treat
toxoplasma infection is oﬀered in many European
countries [1±4]. However, evidence for the eﬀective-
ness of prenatal treatment on the risk of mother-to-
child transmission of infection and on neurological or
visual manifestations in infected children, is limited.
Two systematic reviews showed that no controlled
trials have been conducted [5, 6] and most of the
observational studies lacked an untreated comparison
group as almost all infected women identi®ed pre-
* Author for correspondence: Department of Paediatric Epi-
demiology and Biostatistics, Institute of Child Health, 30, Guilford
Street, London, WC1N 1EH, UK.
natally were treated [7]. However, one recent study [8]
showed no evidence for an eﬀect of prenatal treatment
on mother-to-child transmission but a reduction in
the risk of neurological signs at 1 year of age.
As there are substantial diﬀerences in the screening
and treatment protocols operating in diﬀerent
European centres, comparison of the risks of trans-
mission and clinical manifestations between centres
provides indirect evidence for the relative eﬀectiveness
of diﬀerent testing and treatment protocols. We
therefore sought cohort data from four centres
operating diﬀerent protocols. For example in Lyon,
France, susceptible, IgG-negative women were re-
tested monthly to detect seroconversion, compared






































Monthly (1) Spiramycin alone








P&S for 3 weeks; then
spiramycin until weight
"5 kg, then fansidar for
12months
Paediatric examinations:a t%2 weeks,
then at 2, 5, 8, 12, 15, 18, 24,
30, 36 months, then annually
Ophthalmoscopy (direct}indirect): at
%2 weeks, 2, 5, 8 and 12 months,
then annually.
Cranial imaging: ultrasound and skull
x-ray at %2 weeks.
Austria
1992±5
12, 20, 32 weeks (1) Spiramycin alone if
!16 weeks gestation**
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P&S alternating 6 weekly
with spiramycin for
12 months
Paediatric examinations: at birth, 3,
6, 9 and 12 months and then annually.
Ophthalmoscopy (indirect): at %3
months, 12 months, then annually.
Cranial imaging: ultrasound %3
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weeks, at 3, 6, 9 12 months then
annually.
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annually.
Cranial imaging: ultrasound and
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Not treated Paediatric examinations: at birth,
unspeci®ed intervals during the
®rst year, then annually.
Ophthalmoscopy (indirect): at least
once %12 months, then annually.
Cranial imaging: ultrasound and skull
x-ray at %12 months.
P&S, pyrimethamine and sulfadiazine.
* Recommended re-test interval for IgG negative women. Actual dates at last negative and ®rst positive IgG test for each individual woman were included in the analysis.
 Recommended schedule for follow-up. Actual dates at examination used in the analysis.
 Based on neonatal ®lter paper sample.
Prenatal treatment:
 Continued until delivery.
 Lyon: Pyrimethamine (50mg}day); sulfadiazine (3 g}day) plus folinic acid. Spiramycin (3 g}day).
** Austria: Pyrimethamine (50 mg ®rst dose, then 25mg}day); sulfadiazine (1±5 g ®rst dose, then 0±75 g}day) plus folinic acid. Spiramycin (3 g}day).
 Netherlands: Spiramycin 3 g}day, sulfadiazine 3 g}day.
Postnatal treatment:
 Lyon: Pyrimethamine (3mg}kg every 3 days), sulfadiazine (75mg}kg per day) plus folinic acid. Spiramycin (125mg}kg per day). Fansidar consists of pyrimethamine
(6mg}kg every 10 days) and sulphadoxine (125mg}kg every 10 days).
 Austria: Pyrimethamine (1mg}kg per day), sulfadiazine (85mg}kg per day) plus folinic acid. Spiramycin (100mg}kg per day).
 Denmark: Pyrimethamine (1mg}kg per day), sulfadiazine (100mg}kg per day) plus folinic acid. Spiramycin (100mg}kg per day).116 R. Gilbert and others
latter was a research study and is not routine practice)
[9]. The type of treatment and dosage regimens also
varied, and in Denmark, infected women were
identi®ed by retrospective testing of stored prenatal
samples and received no prenatal treatment [10].
However, comparisons between centres may be mis-
leading if they do not take account of diﬀerences in
the distribution of gestation at maternal infection, a
factor that strongly aﬀects the risks of transmission
and manifestations [11]. In addition, women referred
due to suspected abnormalities in the fetus or neonate,
should be excluded, because selection bias favouring
inclusion of children with abnormalities due to
congenital toxoplasmosis will exaggerate estimates of
the risks of transmission and clinical manifestations
for children of women identi®ed by screening.
We analysed individual patient data for cohorts of
infected women and their children from four centres
(Lyon, Austria, Denmark, The Netherlands). All four
centres achieved high rates of follow-up. Collection of
precise dates of key events made it possible to
minimize selection bias and to standardize the risk
estimates for gestation at maternal seroconversion.
METHODS
For each centre, we included pregnant women
diagnosed with toxoplasma infection during a time
period when: (a) screening was routine; (b) standard
treatment and follow up protocols were in operation;
(c) the rate of follow up beyond 12 months postnatal
age was consistently high (greater than 90%); and (d)
local databases allowed identi®cation of all women
diagnosed with toxoplasma infection. Only women
with evidence of seroconversion during pregnancy
(change from undetectable to detectable toxoplasma-
speci®cIgGantibodies) wereincluded.Theserological
tests used varied between centres and have been
summarized elsewhere [9±12]. In brief, in Lyon,
diagnosis of seroconversion was based on a com-
mercial ELISA run in parallel with an automated
immuno¯uorescent assay for IgG [11]; in Austria, on
the dye test or, if not performed, an immuno-
¯uorescent antibody test; and in The Netherlands, on
an in-house ELISA [13, 14]. In Denmark, infected
women were identi®ed by retrospective testing of
stored prenatal samples after detection of speci®c IgG
on newborn ®lter paper blood samples. Negative
prenatal samples were con®rmed by the dye test [10].
In all centres, detection of speci®c IgG or IgM
antibodies was con®rmed by additional tests for these
antibodies.
Criteria for diagnosing congenital toxoplasmosis
werethe persistence of speci®c IgG beyond12 months,
or in non-live births, a positive PCR or culture result
based on the analysis of amniotic ¯uid or fetal
products. Absence of congenital infection was de®ned
by undetectable speci®c IgG antibodies in the absence
of treatment. Clinical manifestations were de®ned as
the detection of intracranial calci®cation, hydro-
cephalus or retinochoroiditis postnatally or, in non-
live births, by fetal ultrasound or at autopsy.
In an eﬀort to minimize selection bias, datasets were
scrutinized for mother±child pairs referred due to
infection or manifestations in the fetus or child. All
mother±childpairsnotmeetingthelocalcentrecriteria
for seroconversion, or with non-sequential dates for
seroconversion, fetal diagnosis, and detection of fetal
or neonatal anomalies, were excluded. Pregnancies
terminated for toxoplasma infection were included.
Terminations for other reasons, or pregnancies ending
in spontaneous abortion or for which congenital
infection status was not known were recorded but
excluded from the analysis.
Protocols for testing, treatment and follow up of
mother±child pairs are summarized in Table 1 and
have been reported in detail [9±12]. Except for The
Netherlands, all centres treated infected children for
6±12 months postnatally. Consequently, we could
investigate the eﬀect of prenatal but not postnatal
treatment on the risk of clinical manifestations, as few
infected infants were not treated.
Statistical analysis
It was necessary to adjust for the eﬀect of gestation at
maternal infection in the analysis since this varied
between centres (Fig. 1) and has a strong eﬀect on the
risk of both transmission and clinical signs [11]. This
was achieved by indirect standardization [15] using
gestation-speci®c risk estimates previously derived
from the Lyon cohort (reference population) [11].
With these estimates and the observed dates for the
last negative and ®rst positive IgG tests, the expected
number (i.e. assuming Lyon-speci®c risk) of con-
genital infections and children with clinical mani-
festations was calculated for each centre. The ratio of
observed to expected numbers of cases gives a relative
risk, which is adjusted for gestational age at maternal






01 02 03 04 05 06 07 08 09 0 1 0 0
Trimester at maternal infection (%)
1st trimester 2nd trimester
3rd trimester
Time
Fig. 1. Estimated proportions of women seroconverting
during the ®rst, second and third trimesters according to
centre.
factthat maternalseroconversion could have occurred
at any time between the last negative and ®rst positive
serological tests. We assumed that maternal infection
was equally likely throughout this interval and
estimated the expected numbers of cases based on an
average of the risk for the period between the last
negative and ®rst positive test dates. Also, as the
duration of clinical follow-up was variable, the risk of
clinical signs was standardized to age 3 years using the
Kaplan±Meier method. Con®dence intervals (CIs)
were derived by assessing statistical uncertainty in the
observed number of events, using exact binomial
methods or standard errors from the Kaplan Meier
analysis.
If the assumption that maternal infection was
equally likely throughout pregnancy was wrong, the
resulting error would have been greatest in the Danish
cohort,forwhichtheintervalbetweenthelastnegative
and ®rst positive test was longest. For example, if the
incidence of maternal infection decreased during
pregnancy, the adjusted relative risk of transmission
would have been underestimated and the risk of
manifestations overestimated.
RESULTS
The number of mother±child pairs identi®ed by
seroconversion was 592 in Lyon, 135 in Austria, 133
in Denmark and 52 in The Netherlands. The number
of infected pregnancies ending in a live birth or
termination and for which data on congenital in-
fection status were available was 549 (93%), 133
(99%), 123 (92%), and 51 (98%) respectively. The
median postnatal follow-up ranged from 15 months in
Austria to 54 months in Lyon and The Netherlands.
Numbers of seroconverting women, infected children
and infected children with manifestations are sum-
marized in Tables 2 and 3. The proportion of women
treated prenatally was 94% (516}549) in Lyon, 92%
(122}133) in Austria, 0% in Denmark and 51%
(26}51) in The Netherlands. In Lyon, where the type
of treatment depended on gestation at infection and
the results of fetal diagnosis, pyrimethamine-
sulfadiazine was prescribed to 19% (108}564) of the
seroconverting women and 39% (61}156) of the
women with an infected child}fetus.
The crude transmission risk was similar in all
centres, ranging from 21 to 28%. However, there were
marked diﬀerences between the relative risks of
transmission adjusted for weeks of gestation at
maternal infection. In Denmark, where no women
were treated, and in The Netherlands, where only
50% were treated, the adjusted risks of transmission
were lower than in Lyon and Austria where over 90%
of women were treated (upper limit 95% CI for
Denmark and The Netherlands 0±81 and 1±01 re-
spectively). The relative risk of transmission was
similar in Austria and Lyon.
The estimated risk of clinical manifestations by age
3 years ranged from 9 to 33% and was signi®cantly
lower in Austria (adjusted relative risk 0±19 (0±04, 0±51)
compared with Lyon. The adjusted relative risks of
clinical manifestations in Denmark and The
Netherlands did not diﬀer signi®cantly from Lyon,
although in Denmark the upper con®dence limit was
1±08. The adjusted relative risk estimates were
imprecise,duetothe smallnumberofaﬀected children
and the fact that not all children were followed up to
3 years.
DISCUSSION
Unexpectedly, we found no evidence that the risk of
mother-to-child transmission of infection was lower in
centres operating the more intensive prenatal treat-
ment protocols (de®ned by the frequency of sero-
logical testing of susceptible women, the use of
pyrimethamine-sulfadiazine, treatment dosages and
the proportion of women treated). The pattern of
results was inconsistent. The risk of transmission was
lowest in Denmark, where women were not treated
and the risk of clinical manifestations was lowest in
Austria, where women received intensive treatment.
The strengths of our study are that we attempted to
minimize selection bias by excluding women identi®ed
on the basis of infected or aﬀected fetuses or children,
we allowed for the variation in gestation at maternal118 R. Gilbert and others











Relative risk of transmission
Unadjusted Adjusted (95% CI)
Lyon 549 94 156 (28) 1±00 1±00
Austria 131 90 34 (26) 0±92 1±24 (0±88, 1±59)
Denmark 123 0 26 (21) 0±74 0±59 (0±41, 0±81)
Netherlands 51 51 12 (24) 0±83 0±65 (0±37, 1±01)
seroconversion, and we adjusted for the diﬀerential
length of follow up. One explanation for the lack of an
eﬀect of prenatal treatment is that transmission occurs
predominantly during the parasitaemic phase of
maternal infection which usually ceases as soon as the
woman develops a serological response [16±19]. If
true, treatment would inevitably be given too late to
prevent transmission. However, interpretation of
diﬀerences in the risk of transmission should be made
with caution as diﬀerences attributable to prenatal
treatment may have been masked by other centre-
speci®c factors. For example, the lower risks of
transmission in Denmark and The Netherlands
compared with Lyon and Austria, may have been due
to diﬀerent cut-oﬀs for serological tests, or to failure
to exclude selection bias in Lyon and Austria.
Alternatively, there may have been underlying geo-
graphical variations in the risk of transmission,
possibly attributable to variation in the source of
ingested tissue cysts (undercooked meat) or oocysts
(excreted by cats and ingested in contaminated soil,
food or water [20]). The parasite load released from a
single tissue cyst is many fold higher than for oocysts
[16], and in animal experiments, parasite inoculum
has been strongly associated with the risk of mother-
to-fetus transmission [16].
The signi®cantly lower risk of clinical mani-
festations in children followed in Austria should be
interpreted cautiously in view of the retrospective
identi®cation of this cohort and the small number of
infected (n¯34) and aﬀected (n¯3) children. The
results may re¯ect a bene®cial eﬀect of prenatal
treatment with pyrimethamine-sulfadiazine, pre-
scribed to 90% of women, on the risk of clinical
manifestations in infected children. Unlike spira-
mycin, pyrimethamine-sulfadiazine cross the placenta
[16] and the fetal blood±brain barrier [21]. However, if
prenatal treatment with pyrimethamine-sulfadiazine
is eﬀective, we would have expected to see the highest
risk of clinical manifestations in Denmark, where no
women were treated. An intermediate risk would have
been expected in The Netherlands, where 51% of
women were treated with spiramycin and sulfadiazine,
and in Lyon, where 94% of women were treated
prenatally but only 39% of women with infected
fetuses received pyrimethamine-sulfadiazine.
Two other studies have analysed the eﬀect of
prenatal treatment after adjustment for gestation at
maternal infection. The results are contradictory.
Foulon et al. [8] reported that prenatal treatment had
no eﬀect on mother-to-child transmission of infection,
but signi®cantly reduced the risk of manifestations at
1 year of age. These ®ndings, based on 144 con-
secutive,infectedwomenreferredto®vefetalmedicine
centres, may represent a bene®cial eﬀect of treatment
or may be explained by selection bias favouring
inclusion of untreated women referred due to
suspected abnormalities in the fetus or child. In a
separate analysis of clinical manifestations in 181
infected children born to 704 women followed in Lyon
(of whom 549 seroconverters are included in the
present report), we found no evidence of a diﬀerence
in the risk of clinical manifestation at 3 years in
children whose mothers were treated prenatally with
pyrimethamine-sulfadiazine compared with spira-
mycin or no treatment (adjusted odds ratio 0±89 95%
CI: 0±41±1±88) [22]. Selection bias was minimized in
the Lyon cohort by exclusion of women referred due
to suspicion of infection or clinical manifestations in
the fetus [11, 22].
There is no clear evidence from biological studies
that treatment reduces the risk of clinical mani-
festation of congenital toxoplasmosis. Neither spira-
mycin nor pyrimethamine-sulfadiazine are eﬀective
against the encysted, bradyzoite form of the parasite
[23, 24]. Fetal infection and tissue damage is caused
by the tachyzoite form of the parasite, but trans-
formation to bradyzoite starts to occur within days
of infection [16, 25, 26], probably coinciding with
serological and cell mediated responses [16, 25].
Consequently, as prenatal treatment is always given












































































































































































































































































































































































































































































































































































































































may be too late to prevent manifestations. A further
possibility is that cell damage in the brain and eye is
due principally to the immune response to infection
[27±29] rather than destruction by the parasite. The
eﬀect of antibiotics on these immune processes in the
fetus is unknown.
Finally, there is a lack of information on the
association between intracranial lesions and sub-
sequent developmental impairment. Further studies
are required to determine the eﬀect of prenatal
treatment on visual and developmental impairment in
childhood.
Our ®ndings provide no evidence that prenatal
treatment reduces the risks of mother to child
transmission of toxoplasma infection. The low risk of
clinical manifestations in Austria may be explained by
the widespread use of pyrimethamine-sulfadiazine in
infected women. However, further studies are needed
to con®rm or refute these ®ndings.
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